Vanda Pharmaceuticals stock falls after anxiety drug trial fails
Related news
- Here are the major earnings before the open Thursday
- Lockheed Martin plans 6K U.S. jobs in $300M Texas expansion
- Azz raises fiscal 2027 outlook to $1.825B-$1.875B sales and $7-$7.30 adjusted EPS following record Q2
- Bank of America expects 2027 NII to rise 8% or more as it embeds $1.2B regulatory settlement costs
- Gold and silver sink as U.S. inflation data tops expectations, boosting Fed rate hike bets
-
Exclusive-Fed’s Daly says rate hikes likely needed, but not urgently
- Regeneron a new Buy at UBS as Street undervalues Dupixent's future
- Fairfax named strategic buyer for 60.72% stake in India's IDBI Bank